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Dr Darwin Eton (Chicago, Ill): How do you know the cells
are still there 24 hours or 48 hours after injection? Is this a cell
therapy, or is it actually a drug delivery system where the cells get
into the tissue, lyse, and release all the cytokines into the tissue?
How many mice were there in each group?
DrRobertA.Brenes.DrEton, thank you for your questions. In
our study, we did not evaluate if the cells are present 24 to 48 hours
after injection; therefore, I amunable to comment on this.We also did
not evaluate if it is the effector cells or the cytokines released into the
tissue that lead to angiogenesis. However, we believe it may be a
combination of themononuclear cells, endothelial progenitor cells, as
well as the cytokines that all contribute to the angiogenesis seen. In
our primary experiment,wehad ann value of 20mice,with a fewmice
removed at each time point for histological analysis.his is the acute limb ischemia, not the chronic limb ischemia.
owever, the chronic limb ischemia model can be made and
ctually has been utilized by waiting for 4 weeks or 6 after the initial
urgery before starting the treatment. Is this model as durable to
ait like 4 or 6 weeks to create chronic limb ischemia?
Dr Brenes. Dr Yamanouchi, thank you for your comments.
e recognize that our model, as well as others described in the
iterature, are acute models of limb ischemia. C57BL/6 mice
egain their flow spontaneously without cell injection by 4 to 6
eeks post ligation. Therefore, one must study the treatment
odality early after inducing ischemia to see maximal effect. Inter-
stingly, our lab has shown that aged mice have a delayed sponta-
eous recovery to flow as well as functional score. We believe these
ice may be a better model to test cell intervention in more of a
chronic” setting with delayed injections.
